HRSA published its revised 340B Rebate Model Pilot on August 3. Two days later, six senators introduced a bill that would require HHS to shut it down. If you're trying to track whether the rebate model is actually going to happen, this is the development that matters most right now, more than the litigation history, more than the comment letters.

What the SUSTAIN 340B Act Actually Does

The Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future of 340B Act, SUSTAIN 340B for short, is a bipartisan bill introduced August 5 by Senators Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine, John Boozman, and John Hickenlooper. It comes out of the Senate's bipartisan 340B working group, sometimes called the "Gang of Six," which has been circulating discussion drafts of broader 340B reform for months.

SUSTAIN 340B is not a single-issue bill about the rebate model. It covers a range of 340B provisions, including new transparency and reporting requirements and language that would bar manufacturers from imposing conditions on contract pharmacy access. But one provision speaks directly to the pilot HRSA just revised: it declares it the sense of Congress that 340B is meant to function as a point-of-sale discount, not a rebate, and it would require HHS to wind down the Rebate Model Pilot, or anything substantially similar to it, within one year of enactment. In its place, the bill directs HHS toward a data clearinghouse model instead.

‍

Why This Is a Different Kind of Threat Than the Lawsuit

The version of the rebate pilot targeting January 2026 was stopped by a federal court, and the D.C. Circuit has already ruled that manufacturers can't run a rebate model without HRSA's sign-off. Those are legal constraints. SUSTAIN 340B is a legislative one, and it works differently.

A court can only rule on whether HRSA followed the law in how it built this pilot. Congress can simply decide the pilot shouldn't exist at all, regardless of how well HRSA justifies it. That's a categorically different kind of risk to plan around.

It's also worth being clear-eyed about what a bill introduction actually means. SUSTAIN 340B has bipartisan sponsors and real momentum behind it, but it hasn't been marked up, hasn't passed a committee, and isn't law. Bills with broad support still stall regularly, especially ones that touch a program as contested as 340B. Nothing about this bill changes the January 1, 2027 effective date HRSA has on the books today.

The Clearinghouse Idea Just Became More Than a Suggestion

Covered entity commenters proposed a centralized clearinghouse model during HRSA's comment period, as an alternative to the rebate model, and HRSA rejected it in the August 3 notice, arguing it would just be an enhanced claims-modifier system without the compliance incentive a rebate model creates. The AHA has continued pushing the clearinghouse idea publicly, including in a fact sheet published August 7.

SUSTAIN 340B is the first time that alternative has shown up in actual legislative text rather than a comment letter or a fact sheet. That matters regardless of whether this specific bill becomes law, because it establishes the clearinghouse model as the leading alternative on the table if the rebate pilot doesn't survive in its current form.

What to Do With This Information Right Now

Don't treat this as a reason to stop preparing. Manufacturer applications for the pilot are still due August 24, with approvals expected by September 24, and none of that changes because a bill was introduced. If a manufacturer you work with gets approved, you'll still be dealing with the rebate mechanics in this pilot on the current timeline, at least until something more definitive happens on the legislative or legal side.

What it does mean is that "wait and see" is now a two-track question, not one. You're watching whether HRSA's pilot survives a legal challenge, and separately, whether Congress moves on a bill that would kill it outright regardless of the litigation's outcome. Those two tracks could resolve in either order, or not at all this year.

How RxTrail Handles It

We're tracking SUSTAIN 340B alongside manufacturer approvals and the litigation docket, not as three separate news items but as three inputs into the same planning question: what should your organization actually build toward right now. Our job is telling you when one of those tracks moves in a way that changes your specific exposure. Your job is deciding how much operational change to commit to while all three are still open.

‍

Frequently Asked Questions

Who's behind the SUSTAIN 340B Act? 

Six senators introduced it on August 5: Jerry Moran (R-KS), Tammy Baldwin (D-WI), Shelley Moore Capito (R-WV), Tim Kaine (D-VA), John Boozman (R-AR), and John Hickenlooper (D-CO). They make up the Senate's bipartisan 340B working group, which had already been circulating discussion drafts of broader 340B reform before this bill was formally introduced.

Does this bill mean the rebate pilot is dead?

 No. It's a bill, not a law. It would need to pass the Senate, pass the House, and be signed, or survive some other legislative path, before it has any binding effect.

If it passes, does it undo the pilot immediately?

 No. As written, it gives HHS up to a year from enactment to wind the pilot down, not an immediate stop.

Does this affect the August 24 manufacturer application deadline?

 Not directly. That deadline exists under HRSA's current notice, which remains in effect unless a court or Congress changes it.

Should we stop preparing for the rebate pilot because of this bill?

 Not yet. Track it, but don't let it substitute for finding out whether your specific manufacturer relationships are affected by the pilot as it exists today.

‍